"ELAV-Like Protein 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An RRM protein that binds to the 3'-UTR region of mRNAs and increases their stability. In EMBRYONIC STEM CELLS, it binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs and preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), to stabilize them and promote differentiation.
| Descriptor ID |
D000067780
|
| MeSH Number(s) |
D12.776.157.725.813.500.250 D12.776.664.962.813.500.250
|
| Concept/Terms |
ELAV-Like Protein 1- ELAV-Like Protein 1
- ELAV Like Protein 1
- HuR Paraneoplastic Encephalomyelitis Antigen
- HuR Protein
- Protein, HuR
- ELAVL1 protein
- protein, ELAVL1
- HuR Antigen
- Antigen, HuR
|
Below are MeSH descriptors whose meaning is more general than "ELAV-Like Protein 1".
Below are MeSH descriptors whose meaning is more specific than "ELAV-Like Protein 1".
This graph shows the total number of publications written about "ELAV-Like Protein 1" by people in this website by year, and whether "ELAV-Like Protein 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ELAV-Like Protein 1" by people in Profiles.
-
Amreddy N, Ahmed RA, Munshi A, Ramesh R. Tumor-Targeted Dendrimer Nanoparticles for Combinatorial Delivery of siRNA and Chemotherapy for Cancer Treatment. Methods Mol Biol. 2020; 2059:167-189.
-
Amreddy N, Babu A, Panneerselvam J, Srivastava A, Muralidharan R, Chen A, Zhao YD, Munshi A, Ramesh R. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018 02; 14(2):373-384.
-
Muralidharan R, Mehta M, Ahmed R, Roy S, Xu L, Aubé J, Chen A, Zhao YD, Herman T, Ramesh R, Munshi A. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 2017 08 30; 7(1):9694.
-
Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. . 2017 08; 16(8):1470-1486.
-
Mehta M, Basalingappa K, Griffith JN, Andrade D, Babu A, Amreddy N, Muralidharan R, Gorospe M, Herman T, Ding WQ, Ramesh R, Munshi A. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016 10 04; 7(40):64820-64835.
-
Muralidharan R, Babu A, Amreddy N, Basalingappa K, Mehta M, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47.
-
Muralidharan R, Panneerselvam J, Chen A, Zhao YD, Munshi A, Ramesh R. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015 Dec; 22(12):581-90.
-
Díaz-Muñoz MD, Bell SE, Turner M. Deletion of AU-rich elements within the Bcl2 3'UTR reduces protein expression and B cell survival in vivo. PLoS One. 2015; 10(2):e0116899.
-
Anant S, Houchen CW. HuR and TTP: two RNA binding proteins that deliver message from the 3' end. Gastroenterology. 2009 May; 136(5):1495-8.
-
Sureban SM, Murmu N, Rodriguez P, May R, Maheshwari R, Dieckgraefe BK, Houchen CW, Anant S. Functional antagonism between RNA binding proteins HuR and CUGBP2 determines the fate of COX-2 mRNA translation. Gastroenterology. 2007 Mar; 132(3):1055-65.